4.6 Article

Magnetic characterization of rare-earth oxide nanoparticles

Journal

APPLIED PHYSICS LETTERS
Volume 117, Issue 12, Pages -

Publisher

AIP Publishing
DOI: 10.1063/5.0023466

Keywords

-

Funding

  1. Rowland Fellowship
  2. Rowland Institute
  3. Harvard Office of Undergraduate Research and Fellowships

Ask authors/readers for more resources

High saturation magnetization and hysteresis-less magnetic responses are desirable for nanoparticles in scientific and technological applications. Rare-earth oxides are potentially promising materials because of their paramagnetism and high magnetic susceptibility in the bulk, but the magnetic properties of their nanoparticles remain incompletely characterized. Here, we present full M-H loops for commercial RE2O3 nanoparticles (RE = Er, Gd, Dy, Ho) with radii from 10-25nm at room temperature and 4K. The magnetic responses are consistent with two distinct populations of atoms, one displaying the ideal Re3+ magnetic moment and the other displaying a sub-ideal magnetic moment. If all sub-ideal ions are taken to be on the surface, the data are consistent with approximate to 2 - 10 nm surface layers of reduced magnetization. The magnetization of the rare-earth oxide nanoparticles at low temperatures (1.3-1.9 T) exceeds that of the best iron-based nanoparticles, making rare-earth oxides candidates for use in next-generation cryogenic magnetic devices that demand a combination of hysteresis-less response and high magnetization.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Physics, Applied

Accelerated nanoscale magnetic resonance imaging through phase multiplexing

B. A. Moores, A. Eichler, Y. Tao, H. Takahashi, P. Navaretti, C. L. Degen

APPLIED PHYSICS LETTERS (2015)

Article Nanoscience & Nanotechnology

Exclusively Gas-Phase Passivation of Native Oxide-Free Silicon(100) and Silicon(111) Surfaces

Ye Tao, Roland Hauert, Christian L. Degen

ACS APPLIED MATERIALS & INTERFACES (2016)

Article Chemistry, Multidisciplinary

Surface Chemical Tuning of Phonon and Electron Transport in Free-Standing Silicon Nanowire Arrays

Ying Pan, Ye Tao, Guangzhao Qin, Yuriy Fedoryshyn, Yamprasad N. Raja, Ming Hu, Christian L. Degen, Dimos Poulikakos

NANO LETTERS (2016)

Article Chemistry, Multidisciplinary

Magnetometry of Individual Polycrystalline Ferromagnetic Nanowires

Naveen Shamsudhin, Ye Tao, Jordi Sort, Bumjin Jang, Christian L. Degen, Bradley J. Nelson, Salvador Pane

SMALL (2016)

Article Physics, Applied

Wafer-scale photolithography of ultra-sensitive nanocantilever force sensors

Ying Pan, Calder Miller, Kai Trepka, Ye Tao

APPLIED PHYSICS LETTERS (2018)

Article Chemistry, Physical

Experimental and Computational Studies Delineate the Role of Asparagine 177 in Hydride Transfer for E. coli Thymidylate Synthase

Ilya Gurevic, Zahidul Islam, Katarzyna Swiderek, Kai Trepka, Ananda K. Ghosh, Vicent Moliner, Amnon Kohen

ACS CATALYSIS (2018)

Meeting Abstract Oncology

Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Ivan de Kouchkovsky, Li Zhang, Jiaoti Huang, Kai Trepka, Jonathan Chou, Adam Foye, David Shui, Chris Wong, Verena Friedl, Alana Weinstein, Thomas A. Hope, David A. Quigley, Josh Stuart, Tomasz M. Beer, Robert Evan Reiter, Martin E. Gleave, Christopher P. Evans, Felix Y. Feng, Eric Jay Small, Rahul Raj Aggarwal

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease

Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A. Lim, Kevin K. Leung, Emily A. Egusa, Jun Zhu, Li Zhang, Adam Foye, Renuka Sriram, Emily Chan, Youngho Seo, Felix Y. Feng, Eric J. Small, Jonathan Chou, James A. Wells, Rahul Aggarwal, Michael J. Evans

Summary: This study found that CDCP1 is expressed in the majority of mCRPC biopsy samples, including those with low PSMA expression. Radioligand therapy targeting CDCP1 with an antibody was effective in suppressing tumor growth. These findings suggest that CDCP1 may be a potential therapeutic target for treating mCRPC.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

Jonathan Chou, Emily A. Egusa, Sinan Wang, Michelle L. Badura, Fei Lee, Anil P. Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M. Robinson, Veronica Steri, Jiaoti Huang, Yuzhuo Wang, Eric J. Small, Emily Chan, Bradley A. Stohr, Alan Ashworth, Brant Delafontaine, Sylvie Rottey, Keegan S. Cooke, Nooshin Hashemi Sadraei, Brian Yu, Mark Salvati, Julie M. Bailis, Felix Y. Feng, Robert R. Flavell, Rahul Aggarwal

Summary: The expression of DLL3 in de novo and treatment-emergent small-cell/neuroendocrine (t-SCNC) prostate cancer is associated with reduced survival. A PET agent, [89Zr]-DFO-DLL3-scFv, has been developed to detect DLL3 levels in mouse SCNC models. The DLL3-targeted bispecific T-cell engager (BiTE) immunotherapy, AMG 757 (tarlatamab), exhibits potent and durable antitumor activity in patient-derived xenograft models.

CANCER RESEARCH (2023)

Article Oncology

Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer

Shalini Chopra, Kai Trepka, Sasank Sakhamuri, Alberto Carretero-Gonzalez, Jun Zhu, Emily Egusa, Jie Zhou, Kevin Leung, Ning Zhao, Nima Hooshdaran, Felix Y. Feng, James A. Wells, Jonathan Chou, Michael J. Evans

Summary: This study confirms the expression of CDCP1 in bladder cancer and suggests the potential of CDCP1-targeted radiotherapy as a treatment option for bladder cancer patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells

Jonathan Chou, Kai Trepka, Martin Sjostrom, Emily A. Egusa, Carissa E. Chu, Jun Zhu, Emily Chan, Ewan A. Gibb, Michelle L. Badura, Alberto Contreras-Sanz, Bradley A. Stohr, Maxwell Meng, Raj S. Pruthi, Yair Lotan, Peter C. Black, Sima P. Porten, Vadim S. Koshkin, Terence W. Friedlander, Felix Y. Feng

Summary: In this study, we investigated the expression levels of the drug target TROP2 across different molecular subtypes of bladder cancer in multiple patient cohorts and cell lines. We found high levels of TROP2 in most subtypes except in the neuroendocrine subtype. Overall, TROP2 gene expression is higher than NECTIN4 gene expression, and cells resistant to enfortumab vedotin (EV), a NECTIN4-targeting antibody-drug conjugate, remain sensitive to sacituzumab govitecan (SG). Our findings suggest that SG may be effective across most bladder cancer subtypes, including the bladder cancers previously treated with EV.

EUROPEAN UROLOGY ONCOLOGY (2022)

Article Materials Science, Multidisciplinary

A Robust Metal Oxide Thin Film with Cryogenic Saturation Magnetization Exceeding 2 Tesla

Kai Trepka, Roland Hauert, Claudia Cancellieri, Ye Tao

MATTER (2020)

No Data Available